{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:47:51Z","timestamp":1790347671537,"version":"4.1.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Introduction\/Aims<\/jats:title><jats:p>Myasthenia Gravis (MG) is a common neuromuscular junction disorder that is primarily mediated by anti-acetylcholine receptor antibodies (AChR-Ab). However, using AChR-Ab titers to predict MG severity and improvement remains controversial. This study aims to explore the relationship between AChR-Ab titers and AChR-Ab rate of change (RR-AChR-Ab, %) and MG scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used a prospective study approach, and included 62 patients with generalized MG (GMG) who were positive for AChR-Ab. We measured AChR-Ab titers, MGFA-QMGS, and MG-ADL scores at baseline (before treatment) and at 3 and 6\u202fmonths into treatment. Pearson and Spearman correlation analyses were used to study the relationships between changes in AChR-Ab titers, rates of change, and MG scores.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>(1) At baseline, there was no correlation between AChR-Ab titers and age, duration of illness, gender, MGFA classification, or presence of thymic abnormalities. (2) The trend of decreasing AChR-Ab titers matched the trend of reduced QMGS and ADL scores. (3) Six months into treatment,there was a correlation between AChR-Ab titer changes and changes in ADL scores. (4) Three months into treatment, RR-AChRAb showed a correlation with the rate of change in ADL at the same time point.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We found the trend of decreased AChR-Ab titers after standardized treatment that was consistent with reductions in QMGS and ADL scores. Additionally, the rate of change in AChR-Ab titers at 3\u202fmonths and the change in AChR-Ab titers at 6\u202fmonths into treatment did reflect improvements in activities of daily living for MG patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2024.1506845","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:11:26Z","timestamp":1736917886000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Exploring the clinical significance of anti-acetylcholine receptor antibody titers, changes, and change rates in Myasthenia Gravis"],"prefix":"10.3389","volume":"15","author":[{"given":"Lijun","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunbei","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"596981","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"115872","DOI":"10.1016\/j.bcp.2023.115872","article-title":"Myasthenia gravis: molecular mechanisms and promising therapeutic strategies","volume":"218","author":"Chen","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/ene.15730","article-title":"Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis","volume":"30","author":"Stascheit","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.neuroscience.2020.03.009","article-title":"Antibodies and receptors: from neuromuscular junction to central nervous system","volume":"439","author":"Vincent","year":"2020","journal-title":"Neuroscience"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molimm.2022.08.018","article-title":"Complement and myasthenia gravis","volume":"151","author":"Sanderson","year":"2022","journal-title":"Mol Immunol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ncl.2018.01.001","article-title":"Nature and action of antibodies in myasthenia gravis","volume":"36","author":"Ruff","year":"2018","journal-title":"Neurol Clin"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3969\/j.issn.1006-2963.2017.03.002","article-title":"A radioimmunoassay for the quantitative evaluation of acetylcholine receptor antibodies and its clinical correlations in myasthenia gravis","volume":"24","author":"Li","year":"2017","journal-title":"Chin J Neuroimmunol Neurol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1073\/pnas.79.1.188","article-title":"Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies","volume":"79","author":"Tzartos","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"ref16","first-page":"289","article-title":"Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis","volume":"59","author":"Aurangzeb","year":"2009","journal-title":"J Pak Med Assoc"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40120-024-00590-0","article-title":"Constructing and validating a nomogram model for short-term prognosis of patients with AChR-ab+ GMG","volume":"13","author":"Liang","year":"2024","journal-title":"Neurol Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/jnnp.56.5.496","article-title":"Clinical implementation of anti-acetylcholine receptor antibodies","volume":"56","author":"Somnier","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jns.2014.05.037","article-title":"Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a south Asian population","volume":"343","author":"Chang","year":"2014","journal-title":"J Neurol Sci"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1756286420935697","DOI":"10.1177\/1756286420935697","article-title":"C3, C5a and anti-acetylcholine receptor antibody as severity biomarkers in myasthenia gravis","volume":"13","author":"Aguirre","year":"2020","journal-title":"Ther Adv Neurol Disord"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.cca.2022.06.017","article-title":"Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients","volume":"533","author":"Shao","year":"2022","journal-title":"Clin Chim Acta"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10072-022-06493-y","article-title":"Nomogram for the acute exacerbation of acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"44","author":"Chen","year":"2023","journal-title":"Neurol Sci"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"649","DOI":"10.2147\/OPTH.S402181","article-title":"Significance of acetylcholine receptor antibody titers in acetylcholine receptor antibody-positive ocular myasthenia gravis: generalization and presence of thyroid autoimmune antibodies and Thymoma","volume":"17","author":"Supawongwattana","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e16280","DOI":"10.1111\/ene.16280","article-title":"Expert consensus recommendations for improving and standardising the assessment of patients with generalised myasthenia gravis","volume":"31","author":"Meisel","year":"2024","journal-title":"Eur J Neurol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1007\/s00415-020-10342-3","article-title":"Acetylcholine receptor antibody positivity rate in ocular myasthenia gravis: a matter of age?","volume":"268","author":"Monte","year":"2021","journal-title":"J Neurol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1212\/wnl.55.1.16","article-title":"Myasthenia gravis: recommendations for clinical research standards. Task Force of the medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e114060","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal","year":"2014","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","article-title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis","volume":"83","author":"Masuda","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00415-018-9056-8","article-title":"Generalization after ocular onset in myasthenia gravis: a case series in Germany","volume":"265","author":"Li","year":"2018","journal-title":"J Neurol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.nmd.2016.11.009","article-title":"Ephedrine treatment for autoimmune myasthenia gravis","volume":"27","author":"Lipka","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/acn3.51121","article-title":"Consistent improvement with eculizumab across muscle groups in myasthenia gravis","volume":"7","author":"Mantegazza","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s10072-015-2236-8","article-title":"Both binding and blocking antibodies correlate with disease severity in myasthenia gravis","volume":"36","author":"Kang","year":"2015","journal-title":"Neurol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","article-title":"Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology","volume":"146","author":"Pham","year":"2023","journal-title":"Acta Neuropathol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00401-022-02493-6","article-title":"Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities","volume":"144","author":"Rose","year":"2022","journal-title":"Acta Neuropathol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e02203","DOI":"10.1002\/brb3.2203","article-title":"No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: a systematic retrospective study involving 67 patients","volume":"11","author":"Wang","year":"2021","journal-title":"Brain Behav"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/mus.27381","article-title":"Rethinking the utility of acetylcholine receptor antibody titer as a pharmacodynamic biomarker for myasthenia gravis","volume":"64","author":"Lee","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0140-6736(79)90823-7","article-title":"Long-term effects of repeated plasma exchange in myasthenia gravis","volume":"1","author":"Newsom-Davis","year":"1979","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/ene.15238","article-title":"The association between anti-acetylcholine receptor antibody level and clinical improvement in myasthenia gravis","volume":"29","author":"Marcuse","year":"2022","journal-title":"Eur J Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: a systematic review and expert appraisal","volume":"30","author":"Meisel","year":"2023","journal-title":"Eur J Neurol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","article-title":"Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome","volume":"92","author":"Kojima","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12883-019-1397-0","article-title":"Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study","volume":"19","author":"Chou","year":"2019","journal-title":"BMC Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"577125","DOI":"10.1016\/j.jneuroim.2019.577125","article-title":"Increased serum acetylcholine receptor \u03b11 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis","volume":"339","author":"Uzawa","year":"2020","journal-title":"J Neuroimmunol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1474-4422(21)00297-0","article-title":"Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders","volume":"21","author":"Punga","year":"2022","journal-title":"Lancet Neurol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"108676","DOI":"10.1016\/j.clim.2021.108676","article-title":"Peripheral blood hsa-circRNA5333-4: a novel biomarker for myasthenia gravis","volume":"224","author":"Lv","year":"","journal-title":"Clin Immunol"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1506845\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:11:30Z","timestamp":1736917890000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1506845\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":48,"alternative-id":["10.3389\/fneur.2024.1506845"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1506845","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"article-number":"1506845"}}